A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Public ClinicalTrials.gov record NCT04916002. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer
Study identification
- NCT ID
- NCT04916002
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Enrollment
- 77 participants
Conditions and interventions
Conditions
Interventions
- cemiplimab Drug
- vidutolimod Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 29, 2021
- Primary completion
- Oct 30, 2024
- Completion
- Oct 30, 2024
- Last update posted
- Dec 4, 2025
2021 – 2024
United States locations
- U.S. sites
- 20
- U.S. states
- 17
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | 35294 | — |
| City of Hope | Duarte | California | 91010 | — |
| UC San Diego Moores Cancer Center | La Jolla | California | 92037-0845 | — |
| University of California | Los Angeles | California | 90095 | — |
| GenesisCare USA | Jacksonville | Florida | 32204 | — |
| Orlando Health Cancer Institute | Orlando | Florida | 32806 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| VA Maryland Health Care System | Baltimore | Maryland | 20814 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Dartmouth Clinical Trial Office | Lebanon | New Hampshire | 03756 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| East Carolina University | Greenville | North Carolina | 27858 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| OU Health Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| Oncology Consultants | Houston | Texas | 77030 | — |
| University of Utah Huntsman Cancer Center | Salt Lake City | Utah | 84112 | — |
| University of Washington | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04916002, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 4, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04916002 live on ClinicalTrials.gov.